---
pmid: '21593166'
title: Cyclophilin A interacts with domain II of hepatitis C virus NS5A and stimulates
  RNA binding in an isomerase-dependent manner.
authors:
- Foster TL
- Gallay P
- Stonehouse NJ
- Harris M
journal: J Virol
year: '2011'
full_text_available: false
full_text_extraction_method: html_abstract_only
pmcid: PMC3126559
doi: 10.1128/JVI.00393-11
---

# Cyclophilin A interacts with domain II of hepatitis C virus NS5A and stimulates RNA binding in an isomerase-dependent manner.
**Authors:** Foster TL, Gallay P, Stonehouse NJ, Harris M
**Journal:** J Virol (2011)
**DOI:** [10.1128/JVI.00393-11](https://doi.org/10.1128/JVI.00393-11)
**PMC:** [PMC3126559](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3126559/)

## Abstract

1. J Virol. 2011 Jul;85(14):7460-4. doi: 10.1128/JVI.00393-11. Epub 2011 May 18.

Cyclophilin A interacts with domain II of hepatitis C virus NS5A and stimulates 
RNA binding in an isomerase-dependent manner.

Foster TL(1), Gallay P, Stonehouse NJ, Harris M.

Author information:
(1)Institute of Molecular and Cellular Biology, Faculty of Biological Sciences, 
University of Leeds, Mount Preston Street, Leeds LS2 9JT, United Kingdom.

NS5A plays a critical, yet poorly defined, role in hepatitis C virus genome 
replication. The protein consists of three domains, each of which is able to 
bind independently to the 3' untranslated region (UTR) of the viral positive 
strand genomic RNA. The peptidyl-prolyl isomerase cyclophilin A (CypA) binds to 
domain II, catalyzing cis-trans isomerization. CypA inhibitors such as 
cyclosporine (CsA) have been shown to inhibit hepatitis C virus (HCV) 
replication. We show here that CypA stimulated domain II RNA binding activity, 
and this stimulation was abrogated by CsA. An isomerase mutant of CypA (H126Q) 
failed to bind to domain II and did not stimulate RNA binding. Finally, we 
demonstrate that the RNA binding of two domain II mutants, the D316E and 
D316E/Y317N mutants, previously shown to exhibit CypA independence for RNA 
replication, was unaffected by CypA. This study provides an insight into the 
molecular mechanism of CypA activity during HCV replication and further 
validates the use of CypA inhibitors in HCV therapy.

DOI: 10.1128/JVI.00393-11
PMCID: PMC3126559
PMID: 21593166 [Indexed for MEDLINE]

## Full Text

Abstract

NS5A plays a critical, yet poorly defined, role in hepatitis C virus genome replication. The protein consists of three domains, each of which is able to bind independently to the 3â€² untranslated region (UTR) of the viral positive strand genomic RNA. The peptidyl-prolyl isomerase cyclophilin A (CypA) binds to domain II, catalyzing cis-trans isomerization. CypA inhibitors such as cyclosporine (CsA) have been shown to inhibit hepatitis C virus (HCV) replication. We show here that CypA stimulated domain II RNA binding activity, and this stimulation was abrogated by CsA. An isomerase mutant of CypA (H126Q) failed to bind to domain II and did not stimulate RNA binding. Finally, we demonstrate that the RNA binding of two domain II mutants, the D316E and D316E/Y317N mutants, previously shown to exhibit CypA independence for RNA replication, was unaffected by CypA. This study provides an insight into the molecular mechanism of CypA activity during HCV replication and further validates the use of CypA inhibitors in HCV therapy.
